Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth

G. Salzano, S. Zappavigna, A. Luce, N. D'Onofrio, M. L. Balestrieri, A. Grimaldi, S. Lusa, D. Ingrosso, S. Artuso, Manuela Porru, C. Leonetti, M. Caraglia, G. De Rosa

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The treatment of glioblastoma (GBM) is a challenge for the biomedical research since cures remain elusive. Its current therapy, consisted on surgery, radiotherapy, and concomitant chemotherapy with temozolomide (TMZ), is often uneffective. Here, we proposed the use of zoledronic acid (ZOL) as a potential agent for the treatment of GBM. Our group previously developed self-assembling nanoparticles, also named PLCaPZ NPs, to use ZOL in the treatment of prostate cancer. Here, we updated the previously developed nanoparticles (NPs) by designing transferrin (Tf)-targeted selfassembling NPs, also named Tf-PLCaPZ NPs, to use ZOL in the treatment of brain tumors, e.g., GBM. The efficacy of Tf-PLCaPZ NPs was evaluated in different GBM cell lines and in an animal model of GBM, in comparison with PLCaPZ NPs and free ZOL. Tf-PLCaPZ NPs were characterized by a narrow size distribution and a high incorporation efficiency of ZOL. Moreover, the presence of Tf significantly reduced the hemolytic activity of the formulation. In vitro, in LN229 cells, a significant uptake and cell growth inhibition after treatment with Tf-PLCaPZ NPs was achieved. Moreover, the sequential therapy of TMZ and Tf-PLCaPZ NPs lead to a superior therapeutic activity compared to their single administration. The results obtained in mice xenografted with U373MG, revealed a significant anticancer activity of Tf-PLCaPZ NPs, while the tumors remained unaffected with free TMZ. These promising results introduce a novel type of easy-to-obtain NPs for the delivery of ZOL in the treatment of GBM tumors.

Original languageEnglish
Pages (from-to)811-830
Number of pages20
JournalJournal of Biomedical Nanotechnology
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

zoledronic acid
Glioblastoma
Transferrin
Nanoparticles
Acids
temozolomide
Growth
Tumors
Therapeutics

Keywords

  • Glioblastoma
  • Self-Assembling Nanoparticles
  • Temozolomide
  • Transferrin
  • Zoledronic Acid

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Salzano, G., Zappavigna, S., Luce, A., D'Onofrio, N., Balestrieri, M. L., Grimaldi, A., ... De Rosa, G. (2016). Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth. Journal of Biomedical Nanotechnology, 12(4), 811-830. https://doi.org/10.1166/jbn.2016.2214

Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth. / Salzano, G.; Zappavigna, S.; Luce, A.; D'Onofrio, N.; Balestrieri, M. L.; Grimaldi, A.; Lusa, S.; Ingrosso, D.; Artuso, S.; Porru, Manuela; Leonetti, C.; Caraglia, M.; De Rosa, G.

In: Journal of Biomedical Nanotechnology, Vol. 12, No. 4, 01.04.2016, p. 811-830.

Research output: Contribution to journalArticle

Salzano, G, Zappavigna, S, Luce, A, D'Onofrio, N, Balestrieri, ML, Grimaldi, A, Lusa, S, Ingrosso, D, Artuso, S, Porru, M, Leonetti, C, Caraglia, M & De Rosa, G 2016, 'Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth', Journal of Biomedical Nanotechnology, vol. 12, no. 4, pp. 811-830. https://doi.org/10.1166/jbn.2016.2214
Salzano, G. ; Zappavigna, S. ; Luce, A. ; D'Onofrio, N. ; Balestrieri, M. L. ; Grimaldi, A. ; Lusa, S. ; Ingrosso, D. ; Artuso, S. ; Porru, Manuela ; Leonetti, C. ; Caraglia, M. ; De Rosa, G. / Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth. In: Journal of Biomedical Nanotechnology. 2016 ; Vol. 12, No. 4. pp. 811-830.
@article{20f3c37f1f07480db67bdbd420729538,
title = "Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth",
abstract = "The treatment of glioblastoma (GBM) is a challenge for the biomedical research since cures remain elusive. Its current therapy, consisted on surgery, radiotherapy, and concomitant chemotherapy with temozolomide (TMZ), is often uneffective. Here, we proposed the use of zoledronic acid (ZOL) as a potential agent for the treatment of GBM. Our group previously developed self-assembling nanoparticles, also named PLCaPZ NPs, to use ZOL in the treatment of prostate cancer. Here, we updated the previously developed nanoparticles (NPs) by designing transferrin (Tf)-targeted selfassembling NPs, also named Tf-PLCaPZ NPs, to use ZOL in the treatment of brain tumors, e.g., GBM. The efficacy of Tf-PLCaPZ NPs was evaluated in different GBM cell lines and in an animal model of GBM, in comparison with PLCaPZ NPs and free ZOL. Tf-PLCaPZ NPs were characterized by a narrow size distribution and a high incorporation efficiency of ZOL. Moreover, the presence of Tf significantly reduced the hemolytic activity of the formulation. In vitro, in LN229 cells, a significant uptake and cell growth inhibition after treatment with Tf-PLCaPZ NPs was achieved. Moreover, the sequential therapy of TMZ and Tf-PLCaPZ NPs lead to a superior therapeutic activity compared to their single administration. The results obtained in mice xenografted with U373MG, revealed a significant anticancer activity of Tf-PLCaPZ NPs, while the tumors remained unaffected with free TMZ. These promising results introduce a novel type of easy-to-obtain NPs for the delivery of ZOL in the treatment of GBM tumors.",
keywords = "Glioblastoma, Self-Assembling Nanoparticles, Temozolomide, Transferrin, Zoledronic Acid",
author = "G. Salzano and S. Zappavigna and A. Luce and N. D'Onofrio and Balestrieri, {M. L.} and A. Grimaldi and S. Lusa and D. Ingrosso and S. Artuso and Manuela Porru and C. Leonetti and M. Caraglia and {De Rosa}, G.",
note = "Ci sarebbe Artuso S. (lavora con Leonetti)che se la prendiamo.. abbiamo il punteggio pieno",
year = "2016",
month = "4",
day = "1",
doi = "10.1166/jbn.2016.2214",
language = "English",
volume = "12",
pages = "811--830",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "4",

}

TY - JOUR

T1 - Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth

AU - Salzano, G.

AU - Zappavigna, S.

AU - Luce, A.

AU - D'Onofrio, N.

AU - Balestrieri, M. L.

AU - Grimaldi, A.

AU - Lusa, S.

AU - Ingrosso, D.

AU - Artuso, S.

AU - Porru, Manuela

AU - Leonetti, C.

AU - Caraglia, M.

AU - De Rosa, G.

N1 - Ci sarebbe Artuso S. (lavora con Leonetti)che se la prendiamo.. abbiamo il punteggio pieno

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The treatment of glioblastoma (GBM) is a challenge for the biomedical research since cures remain elusive. Its current therapy, consisted on surgery, radiotherapy, and concomitant chemotherapy with temozolomide (TMZ), is often uneffective. Here, we proposed the use of zoledronic acid (ZOL) as a potential agent for the treatment of GBM. Our group previously developed self-assembling nanoparticles, also named PLCaPZ NPs, to use ZOL in the treatment of prostate cancer. Here, we updated the previously developed nanoparticles (NPs) by designing transferrin (Tf)-targeted selfassembling NPs, also named Tf-PLCaPZ NPs, to use ZOL in the treatment of brain tumors, e.g., GBM. The efficacy of Tf-PLCaPZ NPs was evaluated in different GBM cell lines and in an animal model of GBM, in comparison with PLCaPZ NPs and free ZOL. Tf-PLCaPZ NPs were characterized by a narrow size distribution and a high incorporation efficiency of ZOL. Moreover, the presence of Tf significantly reduced the hemolytic activity of the formulation. In vitro, in LN229 cells, a significant uptake and cell growth inhibition after treatment with Tf-PLCaPZ NPs was achieved. Moreover, the sequential therapy of TMZ and Tf-PLCaPZ NPs lead to a superior therapeutic activity compared to their single administration. The results obtained in mice xenografted with U373MG, revealed a significant anticancer activity of Tf-PLCaPZ NPs, while the tumors remained unaffected with free TMZ. These promising results introduce a novel type of easy-to-obtain NPs for the delivery of ZOL in the treatment of GBM tumors.

AB - The treatment of glioblastoma (GBM) is a challenge for the biomedical research since cures remain elusive. Its current therapy, consisted on surgery, radiotherapy, and concomitant chemotherapy with temozolomide (TMZ), is often uneffective. Here, we proposed the use of zoledronic acid (ZOL) as a potential agent for the treatment of GBM. Our group previously developed self-assembling nanoparticles, also named PLCaPZ NPs, to use ZOL in the treatment of prostate cancer. Here, we updated the previously developed nanoparticles (NPs) by designing transferrin (Tf)-targeted selfassembling NPs, also named Tf-PLCaPZ NPs, to use ZOL in the treatment of brain tumors, e.g., GBM. The efficacy of Tf-PLCaPZ NPs was evaluated in different GBM cell lines and in an animal model of GBM, in comparison with PLCaPZ NPs and free ZOL. Tf-PLCaPZ NPs were characterized by a narrow size distribution and a high incorporation efficiency of ZOL. Moreover, the presence of Tf significantly reduced the hemolytic activity of the formulation. In vitro, in LN229 cells, a significant uptake and cell growth inhibition after treatment with Tf-PLCaPZ NPs was achieved. Moreover, the sequential therapy of TMZ and Tf-PLCaPZ NPs lead to a superior therapeutic activity compared to their single administration. The results obtained in mice xenografted with U373MG, revealed a significant anticancer activity of Tf-PLCaPZ NPs, while the tumors remained unaffected with free TMZ. These promising results introduce a novel type of easy-to-obtain NPs for the delivery of ZOL in the treatment of GBM tumors.

KW - Glioblastoma

KW - Self-Assembling Nanoparticles

KW - Temozolomide

KW - Transferrin

KW - Zoledronic Acid

UR - http://www.scopus.com/inward/record.url?scp=84961692413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961692413&partnerID=8YFLogxK

U2 - 10.1166/jbn.2016.2214

DO - 10.1166/jbn.2016.2214

M3 - Article

VL - 12

SP - 811

EP - 830

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 4

ER -